Hollsteen
← Oracle

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 FY2016: $1.4B · 10-Q 0001193125-15-323532 filed Sep 18, 2015Research and development · Q2 FY2016: $1.4B · 10-Q 0001193125-15-407703 filed Dec 18, 2015Research and development · Q3 FY2016: $1.4B · 10-Q 0001193125-16-510333 filed Mar 18, 2016Research and development · Q4 FY2016: $1.5B · derived · 10-K 0001193125-17-214833 filed Jun 27, 2017Research and development · Q1 FY2017: $1.5B · 10-Q 0001193125-16-713596 filed Sep 19, 2016Research and development · Q2 FY2017: $1.5B · 10-Q 0001193125-16-797253 filed Dec 19, 2016Research and development · Q3 FY2017: $1.5B · 10-Q 0001193125-17-087309 filed Mar 17, 2017Research and development · Q4 FY2017: $1.6B · derived · 10-K 0001193125-18-201034 filed Jun 22, 2018Research and development · Q1 FY2018: $1.6B · 10-Q 0001564590-18-023315 filed Sep 19, 2018Research and development · Q2 FY2018: $1.5B · 10-Q 0001564590-18-031113 filed Dec 19, 2018Research and development · Q3 FY2018: $1.5B · 10-Q 0001564590-19-008273 filed Mar 18, 2019Research and development · Q4 FY2018: $1.5B · derived · 10-K 0001564590-19-023119 filed Jun 21, 2019Research and development · Q1 FY2019: $1.6B · 10-Q 0001564590-18-023315 filed Sep 19, 2018Research and development · Q2 FY2019: $1.5B · 10-Q 0001564590-18-031113 filed Dec 19, 2018Research and development · Q3 FY2019: $1.4B · 10-Q 0001564590-19-008273 filed Mar 18, 2019Research and development · Q4 FY2019: $1.6B · derived · 10-K 0001564590-20-030125 filed Jun 22, 2020Research and development · Q1 FY2020: $1.6B · 10-Q 0001564590-19-034717 filed Sep 13, 2019Research and development · Q2 FY2020: $1.5B · 10-Q 0001564590-19-045966 filed Dec 13, 2019Research and development · Q3 FY2020: $1.5B · 10-Q 0001564590-20-010833 filed Mar 13, 2020Research and development · Q4 FY2020: $1.5B · derived · 10-K 0001564590-21-033616 filed Jun 21, 2021Research and development · Q1 FY2021: $1.6B · 10-Q 0001564590-20-043448 filed Sep 15, 2020Research and development · Q2 FY2021: $1.6B · 10-Q 0001564590-20-056896 filed Dec 11, 2020Research and development · Q3 FY2021: $1.6B · 10-Q 0001564590-21-012539 filed Mar 11, 2021Research and development · Q4 FY2021: $1.7B · derived · 10-K 0001564590-22-023675 filed Jun 21, 2022Research and development · Q1 FY2022: $1.7B · 10-Q 0001564590-21-047772 filed Sep 13, 2021Research and development · Q2 FY2022: $1.8B · 10-Q 0001564590-21-060022 filed Dec 10, 2021Research and development · Q3 FY2022: $1.8B · 10-Q 0001564590-22-009859 filed Mar 11, 2022Research and development · Q4 FY2022: $2.0B · derived · 10-K 0000950170-23-028914 filed Jun 20, 2023Research and development · Q1 FY2023: $2.1B · 10-Q 0001564590-22-031545 filed Sep 13, 2022Research and development · Q2 FY2023: $2.2B · 10-Q 0001564590-22-039278 filed Dec 13, 2022Research and development · Q3 FY2023: $2.1B · 10-Q 0001564590-23-003413 filed Mar 10, 2023Research and development · Q4 FY2023: $2.2B · derived · 10-K 0000950170-24-075605 filed Jun 20, 2024Research and development · Q1 FY2024: $2.2B · 10-Q 0000950170-23-047713 filed Sep 12, 2023Research and development · Q2 FY2024: $2.2B · 10-Q 0000950170-23-069682 filed Dec 12, 2023Research and development · Q3 FY2024: $2.2B · 10-Q 0000950170-24-029904 filed Mar 12, 2024Research and development · Q4 FY2024: $2.2B · derived · 10-K 0000950170-25-087926 filed Jun 18, 2025Research and development · Q1 FY2025: $2.3B · 10-Q 0000950170-24-104905 filed Sep 10, 2024Research and development · Q2 FY2025: $2.5B · 10-Q 0000950170-24-134973 filed Dec 10, 2024Research and development · Q3 FY2025: $2.4B · 10-Q 0000950170-25-037143 filed Mar 11, 2025Research and development · Q4 FY2025: $2.7B · derived · 10-K 0001193125-26-277521 filed Jun 22, 2026Research and development · Q1 FY2026: $2.5B · 10-Q 0001193125-25-200095 filed Sep 10, 2025Research and development · Q2 FY2026: $2.6B · 10-Q 0001193125-25-315925 filed Dec 11, 2025Research and development · Q3 FY2026: $2.6B · 10-Q 0001193125-26-101045 filed Mar 11, 2026Research and development · Q4 FY2026: $2.6B · derived · 10-K 0001193125-26-277521 filed Jun 22, 2026Research and development · Q1 FY2027: $2.4B · 10-Q 0001193125-26-389274 filed Sep 11, 20261,6842,4011,3902,654aQ1 FY2016Q1 FY2027Q1 FY2022
$MResearch and development · Q1 FY2021: $1.6B · 10-Q 0001564590-20-043448 filed Sep 15, 2020Research and development · Q2 FY2021: $1.6B · 10-Q 0001564590-20-056896 filed Dec 11, 2020Research and development · Q3 FY2021: $1.6B · 10-Q 0001564590-21-012539 filed Mar 11, 2021Research and development · Q4 FY2021: $1.7B · derived · 10-K 0001564590-22-023675 filed Jun 21, 2022Research and development · Q1 FY2022: $1.7B · 10-Q 0001564590-21-047772 filed Sep 13, 2021Research and development · Q2 FY2022: $1.8B · 10-Q 0001564590-21-060022 filed Dec 10, 2021Research and development · Q3 FY2022: $1.8B · 10-Q 0001564590-22-009859 filed Mar 11, 2022Research and development · Q4 FY2022: $2.0B · derived · 10-K 0000950170-23-028914 filed Jun 20, 20231,6841,965a1,589Q1 FY2021Q4 FY2022Q1 FY2022
Q1 FY2022
1,684$M
All values (45)
PeriodValue ($M)Status
Q1 FY20272,401reported
Q4 FY20262,614derived
Q3 FY20262,607reported
Q2 FY20262,561reported
Q1 FY20262,491reported
Q4 FY20252,654derived
Q3 FY20252,429reported
Q2 FY20252,471reported
Q1 FY20252,306reported
Q4 FY20242,226derived
Q3 FY20242,248reported
Q2 FY20242,226reported
Q1 FY20242,216reported
Q4 FY20232,226derived
Q3 FY20232,146reported
Q2 FY20232,158reported
Q1 FY20232,093reported
Q4 FY20221,965derived
Q3 FY20221,816reported
Q2 FY20221,754reported
Q1 FY20221,684reported
Q4 FY20211,715derived
Q3 FY20211,621reported
Q2 FY20211,601reported
Q1 FY20211,589reported
Q4 FY20201,479derived
Q3 FY20201,500reported
Q2 FY20201,531reported
Q1 FY20201,557reported
Q4 FY20191,562derived
Q3 FY20191,426reported
Q2 FY20191,475reported
Q1 FY20191,564reported
Q4 FY20181,543derived
Q3 FY20181,496reported
Q2 FY20181,473reported
Q1 FY20181,572reported
Q4 FY20171,608derived
Q3 FY20171,521reported
Q2 FY20171,510reported
Q1 FY20171,520reported
Q4 FY20161,534derived
Q3 FY20161,419reported
Q2 FY20161,444reported
Q1 FY20161,390reported

CSV with all sources · Technical ID: rnd

More metrics for Oracle

Value drivers

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Sources & calculation
Value
$1.7B
Period
Q1 FY2022, ended Aug 31, 2021 · quarterly value (3 months, not cumulative)
Source
10-Q, filed Sep 13, 2021 · 0001564590-21-047772
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$1.7BSep 13, 202110-Q 0001564590-21-047772reported · confidence 1. · current